Showing 1 - 20 results of 44 for search '(( significant clinical case ) OR ( significantly ((greater decrease) OR (a decrease)) ))~', query time: 0.41s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Table 1_Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database.xlsx by Shanshan Wu (348762)

    Published 2025
    “…Positive signals were defined as cases with at least three reports and a lower 95% confidence interval (CI) of ROR greater than one. …”
  5. 5

    Image 1_Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database.pdf by Shanshan Wu (348762)

    Published 2025
    “…Positive signals were defined as cases with at least three reports and a lower 95% confidence interval (CI) of ROR greater than one. …”
  6. 6

    Table 1_Impact of co-infections and immune responses on clinical severity of human adenovirus 3 and 7 infections in hospitalized children with lower respiratory tract infections: a... by Xiaolin Ma (701778)

    Published 2025
    “…</p>Conclusions<p>Hospitalized children with HAdV-7-associated LRTIs exhibit greater severity, multiple infections, and significant potential for greater cellular immune dysregulation compared to those with HAdV-3 infection, indicating a more severe clinical course and distinct pathogenic profiles.…”
  7. 7
  8. 8

    Matched data. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  9. 9

    Nomogram model. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  10. 10

    Flowchart of Study Design and Analysis. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  11. 11

    Multivariate Binary Logistic Regression Analysis. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  12. 12

    ROC curve. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  13. 13

    Unmatched data. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  14. 14

    Calibration curve. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  15. 15

    Decision curves. by Feng Zhang (6548)

    Published 2025
    “…<div><p>Objective</p><p>This study aims to explore factors influencing false-negative results in Interferon-Gamma Release Assay (IGRA) for patients with Pulmonary Tuberculosis (PTB), and develop a nomogram model to predict IGRA false negatives, thereby optimizing clinical diagnosis and treatment decisions.…”
  16. 16

    DataSheet1_Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess.ZIP by Huadong Ke (19937268)

    Published 2024
    “…Furthermore, Berubicin exhibited a particularly high proportion of blood and lymphatic system disease AEs, reaching 45.6%, which was significantly greater than those observed for the other two drugs.…”
  17. 17

    Table1_Clinical efficacy of Fufang Yinhua Jiedu (FFYH) granules in mild COVID-19 and its anti-SARS-CoV-2 mechanism by blocking autophagy through inhibiting the AKT/mTOR signaling p... by Wenlei Wang (1514554)

    Published 2024
    “…No patients progressed to severe or critical cases.</p>Conclusion<p>Our results indicate that FFYH not only has good anti-viral activity against SARS-CoV-2 but also has significant efficacy against COVID-19, indicating that FFYH may be a novel complementary option for treating COVID-19.…”
  18. 18

    Table2_Clinical efficacy of Fufang Yinhua Jiedu (FFYH) granules in mild COVID-19 and its anti-SARS-CoV-2 mechanism by blocking autophagy through inhibiting the AKT/mTOR signaling p... by Wenlei Wang (1514554)

    Published 2024
    “…No patients progressed to severe or critical cases.</p>Conclusion<p>Our results indicate that FFYH not only has good anti-viral activity against SARS-CoV-2 but also has significant efficacy against COVID-19, indicating that FFYH may be a novel complementary option for treating COVID-19.…”
  19. 19
  20. 20